• Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use 

      van Straalen, Joeri W.; Krol, Roline; Giancane, Gabriella; Panaviene, Violeta; Ailioaie, Laura Marinela; Dolezalova, Pavla; Cattalini, Marco; Susic, Gordana; Sztajnbok, Flavio; Maritsi, Despoina; Constantin, Tamas; Sawhney, Sujata; Rygg, Marite; Oliveira, Sheila K.; Nordal, Ellen Berit; Saad-Magalhaes, C; Rubio-Perez, Nadina; Jelusic, Marija; de Roock, Sytze; Wulffraat, Nico; Ruperto, Nicolino; Swart, Joost Frans; International Trials Org, Paediatric Rheumatology (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-09-11)
      Objectives: To describe risk factors for inflammatory bowel disease (IBD) development in a cohort of children with juvenile idiopathic arthritis (JIA).<p> <p>Methods: JIA patients who developed IBD were identified from the international Pharmachild register. Characteristics were compared between IBD and non-IBD patients and predictors of IBD were determined using multivariable logistic regression ...
    • Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study 

      van Straalen, Joeri W.; de Roock, Sytze; Giancane, Gabriella; Consolaro, Alessandro; Rygg, Marite; Nordal, Ellen Berit; Rubio-Pérez, Nadina; Jelusic, Marija; De Inocencio, Jaime; Vojinovic, Jelena; Wulffraat, Nico M.; Bruijning-Verhagen, Patricia C. J.; Ruperto, Nicolino; Swart, Joost F. (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-11-14)
      Background: Etanercept (ETN) and adalimumab (ADA) are considered equally efective biologicals in the treat‑ ment of arthritis in juvenile idiopathic arthritis (JIA) but no studies have compared their impact on patient-reported well-being. The objective of this study was to determine whether ETN and ADA have a diferential efect on patientreported well-being in non-systemic JIA using real-world ...